ARID1A mutations in endometriosis-associated ovarian carcinomas.
By Kimberly C. Wiegand, Sohrab P. Shah, Osama M. Al-Agha, Yongjun Zhao, Kane Tse, Thomas Zeng, J. Senz, M. McConechy, M. Anglesio, S. Kalloger and 34 more. New England Journal of Medicine, 2010
1,661 citations recorded by the source corpus.
Subfields: Molecular Biology, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/3cc716d4e523a7b70ab56b045331bbabf9095f93
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Peter W. Laird
- S. Baylin
- Elaine R. Mardis
- Eric S. Lander
- Hui Shen
- P. Park
- Daniel C. Koboldt
- Manel Esteller
In Reproductive Medicine
Citations in the corpus
- The Somatic Genomic Landscape of Glioblastoma (2013, background): “A role for chromatin organization in GBM pathology, which has been described for cancer types such as ovarian carcinoma (Wiegand et al., 2010) and renal carcinoma (Varela et al.”
- Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder (2011, neutral): “58 × 10−15 ARID1Aa 4 14 0 18 − 13 (13) 1.”
- Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features (2012, background): “inactivation occurs early during malignant transformation of endometriosis [66].”
- Cancer Genetics and Epigenetics: Two Sides of the Same Coin? (2012, neutral): “(Guan et al., 2011; Jones et al., 2010; Wiegand et al., 2010).”
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. (2011, background): “2 M biotinylated peptide substrate (ie, peptide mimicking the H3 tail, H3(21-44)), which has been unmethylated (H3K27me0, open bar or me0), monomethylated (H3K27me1, gray bar or me1) or dimethylated (H3K27me2, black bar or me2) at Lys-27.”